Walgreens Boots Alliance Prepares for Q4 Earnings Report Amid Challenges

Walgreens Boots Alliance, Inc. (WBA), a prominent player in the global healthcare and retail pharmacy sectors, is set to announce its quarterly earnings for Q4 2025. Analysts predict that the company will report adjusted earnings of $0.25 per share, reflecting a significant decline of 35.9% compared to $0.39 per share in the same quarter last year. This earnings report is crucial as it follows a trend where WBA has outperformed Wall Street’s earnings estimates in the past four quarters.

The Deerfield, Illinois-based company has a market capitalization of $10.1 billion and operates through various segments, including U.S. Retail Pharmacy, International, and U.S. Healthcare. For the entirety of fiscal 2025, analysts anticipate an adjusted earnings per share (EPS) of $1.70, a nearly 41% decrease from $2.88 in fiscal 2024.

Recent Performance and Market Response

In recent weeks, Walgreens Boots Alliance has experienced a modest recovery in its stock price following the announcement of its Q3 2025 results on June 26. The company reported an adjusted EPS of $0.38 and revenue of approximately $39 billion. This performance was bolstered by aggressive cost-cutting measures, including executive reductions and strategic store closures. Notably, U.S. retail pharmacy sales rose by 8% to $30.7 billion, and same-store sales increased by 10.3%.

Despite these gains, the long-term outlook for WBA remains cautious. Over the past 52 weeks, shares have declined by 2.6%, underperforming both the S&P 500 Index, which returned 16.8%, and the Consumer Staples Select Sector SPDR Fund, which gained 3.6% during the same period.

Analyst Ratings and Future Outlook

The consensus among analysts regarding WBA stock is measured, resulting in an overall “Hold” rating. Out of 13 analysts covering the stock, only one recommends a “Strong Buy,” while 11 suggest “Hold” and one advises “Moderate Sell.” As of the latest data, the stock is trading above the average analyst price target of $11.54.

As Walgreens Boots Alliance prepares to release its quarterly earnings, the results will be closely monitored by investors and analysts alike. The company’s ability to navigate the ongoing challenges in the retail pharmacy landscape will be pivotal for its future performance.

On the date of this publication, author Sohini Mondal did not hold any positions, directly or indirectly, in the securities mentioned in this article. All information is intended solely for informational purposes. For further details, please refer to the Barchart Disclosure Policy.